Your browser doesn't support javascript.
loading
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
Jones, LaQuita M; Melgar, Katelyn; Bolanos, Lyndsey; Hueneman, Kathleen; Walker, Morgan M; Jiang, Jian-Kang; Wilson, Kelli M; Zhang, Xiaohu; Shen, Jian; Jiang, Fan; Sutter, Patrick; Wang, Amy; Xu, Xin; Tawa, Gregory J; Hoyt, Scott B; Wunderlich, Mark; O'Brien, Eric; Perentesis, John P; Starczynowski, Daniel T; Thomas, Craig J.
  • Jones LM; Division of Oncology and.
  • Melgar K; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Bolanos L; Immunology Graduate Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Hueneman K; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Walker MM; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Jiang JK; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA.
  • Wilson KM; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA.
  • Zhang X; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA.
  • Shen J; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA.
  • Jiang F; Viva Biotech Ltd., Shanghai, China.
  • Sutter P; Viva Biotech Ltd., Shanghai, China.
  • Wang A; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA.
  • Xu X; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA.
  • Tawa GJ; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA.
  • Hoyt SB; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA.
  • Wunderlich M; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA.
  • O'Brien E; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Perentesis JP; Division of Oncology and.
  • Starczynowski DT; Division of Oncology and.
  • Thomas CJ; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
J Clin Invest ; 130(4): 2017-2023, 2020 04 01.
Article en En | MEDLINE | ID: mdl-32149729
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Sistemas de Liberación de Medicamentos / Inhibidores de Proteínas Quinasas / Tirosina Quinasa 3 Similar a fms / Mutación Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Sistemas de Liberación de Medicamentos / Inhibidores de Proteínas Quinasas / Tirosina Quinasa 3 Similar a fms / Mutación Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article